乐观
$53.26
情景价格
$56.540
+0.956 (+1.69%)收盘时
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.
Bruker Corp is currently priced at $58.84, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim. However, the stock has an RSI of 36.731, indicating it is in the oversold territory, which could signal a potential rebound. The recent 5-day change of -6.96% and a significant loss of $65.3 million in Q2 raises concerns about profitability. Therefore, while there are positive catalysts like increased hedge fund ownership and a partnership in superconductors, the risks associated with recent performance and market sentiment suggest holding rather than buying at this time.
Barclays
$70
2026-10-07
Barclays
2026-10-07
目标价
$70
Guggenheim
$72
2026-10-01
Guggenheim
2026-10-01
目标价
$72
Leerink
$80
2026-09-29
Leerink
2026-09-29
目标价
$80
UBS
$65
2026-09-09
UBS
2026-09-09
目标价
$65
TD Cowen
$60
2026-07-15
TD Cowen
2026-07-15
目标价
$60
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Bruker Corporation Releases Human Plasma Proteome Draft Atlas

Bruker Unveils New Mass Spectrometry Technologies for Enhanced Proteomics

Bruker Corporation Secures Multi-System NMR Order from UC Berkeley

Bruker Corporation to Present at Multiple Healthcare Conferences

Bruker Partners with Luvata to Advance Superconductor Technology
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Bruker Corp is currently priced at $58.84, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim. However, the stock has an RSI of 36.731, indicating it is in the oversold territory, which could signal a potential rebound. The recent 5-day change of -6.96% and a significant loss of $65.3 million in Q2 raises concerns about profitability. Therefore, while there are positive catalysts like increased hedge fund ownership and a partnership in superconductors, the risks associated with recent performance and market sentiment suggest holding rather than buying at this time.
14 analysts cover BRKR: 2 rate it Buy, 10 Hold and 2 Sell. The average price target is 52.18.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。